In conclusion, our work demonstrates that miR-329 and miR-449b enhance the therapeutic efficacy of TMZ by reducing motility and spheroid formation, targeting key survival pathways (FAK/Src, and Cyclin D1), modulating NF-κB signaling, and promoting apoptosis in 3D GBM spheroids. This evidence concerns the gene NFKB1 and glioblastoma.